Tags

Type your tag names separated by a space and hit enter

Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting.
Ophthalmology. 2014 Jul; 121(7):1377-82.O

Abstract

PURPOSE

To investigate the efficacy and safety of corneal collagen cross-linking (CXL) with photoactivated riboflavin (photoactivated chromophore for infectious keratitis [PACK]-CXL) in the management of infectious keratitis with corneal melting.

DESIGN

Prospective clinical trial.

PARTICIPANTS

Forty eyes from 40 patients with advanced infectious keratitis and coexisting corneal melting.

METHODS

Twenty-one patients (21 eyes) underwent PACK-CXL treatment in addition to antimicrobial therapy. The control group consisted of 19 patients (19 eyes) who received only antimicrobial therapy.

MAIN OUTCOME MEASURES

The slit-lamp characteristics of the corneal ulceration, corrected distance visual acuity, duration until healing, and complications were documented in each group. The Mann-Whitney U test was used for statistical analysis. P values less than 0.05 were considered statistically significant.

RESULTS

The average time until healing was 39.76 ± 18.22 days in the PACK-CXL group and 46.05 ± 27.44 days in the control group (P = 0.68). After treatment and healing, corrected distance visual acuity was 1.64 ± 0.62 in the PACK-CXL group and 1.67 ± 0.48 in the control group (P = 0.68). The corneal ulceration's width and length was significantly bigger in the PACK-CXL group (P = 0.004 and P = 0.007). Three patients in the control group demonstrated corneal perforation; infection recurred in 1 of them. No serious complications occurred in the PACK-CXL group.

CONCLUSIONS

Corneal CXL with photoactivated riboflavin did not shorten the time to corneal healing; however, the complication rate was 21% in the control group, whereas there was no incidence of corneal perforation or recurrence of the infection in the PACK-CXL group. These results indicate that PACK-CXL may be an effective adjuvant therapy in the management of severe infectious keratitis associated with corneal melting.

Authors+Show Affiliations

Research Institute of Ophthalmology, Cairo, Egypt.Research Institute of Ophthalmology, Cairo, Egypt.Division of Ophthalmology, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.Research Institute of Ophthalmology, Cairo, Egypt.Department of Ophthalmology, Beni-Suef University Hospitals, Cairo, Egypt.Department of Ophthalmology, Beni-Suef University Hospitals, Cairo, Egypt.Research Institute of Ophthalmology, Cairo, Egypt.Department of Ophthalmology and Visual Sciences, Nottingham University Hospitals, Nottingham, United Kingdom.Division of Ophthalmology, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland; Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: farhad@hafezi.ch.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

24576886

Citation

Said, Dalia G., et al. "Collagen Cross-linking With Photoactivated Riboflavin (PACK-CXL) for the Treatment of Advanced Infectious Keratitis With Corneal Melting." Ophthalmology, vol. 121, no. 7, 2014, pp. 1377-82.
Said DG, Elalfy MS, Gatzioufas Z, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 2014;121(7):1377-82.
Said, D. G., Elalfy, M. S., Gatzioufas, Z., El-Zakzouk, E. S., Hassan, M. A., Saif, M. Y., Zaki, A. A., Dua, H. S., & Hafezi, F. (2014). Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology, 121(7), 1377-82. https://doi.org/10.1016/j.ophtha.2014.01.011
Said DG, et al. Collagen Cross-linking With Photoactivated Riboflavin (PACK-CXL) for the Treatment of Advanced Infectious Keratitis With Corneal Melting. Ophthalmology. 2014;121(7):1377-82. PubMed PMID: 24576886.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. AU - Said,Dalia G, AU - Elalfy,Mohamed S, AU - Gatzioufas,Zisis, AU - El-Zakzouk,Ehab S, AU - Hassan,Mansour A, AU - Saif,Mohamed Y, AU - Zaki,Ahmed A, AU - Dua,Harminder S, AU - Hafezi,Farhad, Y1 - 2014/02/25/ PY - 2013/07/15/received PY - 2014/01/05/revised PY - 2014/01/07/accepted PY - 2014/3/1/entrez PY - 2014/3/1/pubmed PY - 2014/9/11/medline SP - 1377 EP - 82 JF - Ophthalmology JO - Ophthalmology VL - 121 IS - 7 N2 - PURPOSE: To investigate the efficacy and safety of corneal collagen cross-linking (CXL) with photoactivated riboflavin (photoactivated chromophore for infectious keratitis [PACK]-CXL) in the management of infectious keratitis with corneal melting. DESIGN: Prospective clinical trial. PARTICIPANTS: Forty eyes from 40 patients with advanced infectious keratitis and coexisting corneal melting. METHODS: Twenty-one patients (21 eyes) underwent PACK-CXL treatment in addition to antimicrobial therapy. The control group consisted of 19 patients (19 eyes) who received only antimicrobial therapy. MAIN OUTCOME MEASURES: The slit-lamp characteristics of the corneal ulceration, corrected distance visual acuity, duration until healing, and complications were documented in each group. The Mann-Whitney U test was used for statistical analysis. P values less than 0.05 were considered statistically significant. RESULTS: The average time until healing was 39.76 ± 18.22 days in the PACK-CXL group and 46.05 ± 27.44 days in the control group (P = 0.68). After treatment and healing, corrected distance visual acuity was 1.64 ± 0.62 in the PACK-CXL group and 1.67 ± 0.48 in the control group (P = 0.68). The corneal ulceration's width and length was significantly bigger in the PACK-CXL group (P = 0.004 and P = 0.007). Three patients in the control group demonstrated corneal perforation; infection recurred in 1 of them. No serious complications occurred in the PACK-CXL group. CONCLUSIONS: Corneal CXL with photoactivated riboflavin did not shorten the time to corneal healing; however, the complication rate was 21% in the control group, whereas there was no incidence of corneal perforation or recurrence of the infection in the PACK-CXL group. These results indicate that PACK-CXL may be an effective adjuvant therapy in the management of severe infectious keratitis associated with corneal melting. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/24576886/Collagen_cross_linking_with_photoactivated_riboflavin__PACK_CXL__for_the_treatment_of_advanced_infectious_keratitis_with_corneal_melting_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(14)00020-7 DB - PRIME DP - Unbound Medicine ER -